RBC Capital Markets reiterated their outperform rating on shares of Ocular Therapeutix Inc. (NASDAQ:OCUL) in a research note published on Tuesday. RBC Capital Markets currently has a $32.00 price target on the biopharmaceutical company’s stock, up from their previous price target of $30.00.

A number of other analysts also recently commented on the company. Royal Bank Of Canada boosted their target price on Ocular Therapeutix from $30.00 to $32.00 and gave the stock an outperform rating in a research report on Tuesday. Zacks Investment Research upgraded Ocular Therapeutix from a hold rating to a buy rating and set a $7.50 target price on the stock in a research report on Friday, August 12th. BTIG Research reiterated a buy rating and set a $18.00 target price on shares of Ocular Therapeutix in a research report on Saturday, October 15th. Finally, JMP Securities assumed coverage on Ocular Therapeutix in a research report on Thursday, August 11th. They set an outperform rating and a $5.84 target price on the stock. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. The company has an average rating of Buy and a consensus price target of $18.56.

Shares of Ocular Therapeutix (NASDAQ:OCUL) traded up 16.60% on Tuesday, reaching $9.20. The company’s stock had a trading volume of 2,174,859 shares. Ocular Therapeutix has a 1-year low of $4.04 and a 1-year high of $14.50. The stock’s market capitalization is $228.89 million. The company has a 50 day moving average of $6.45 and a 200 day moving average of $6.99.

Ocular Therapeutix (NASDAQ:OCUL) last announced its quarterly earnings data on Wednesday, November 9th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.50) by $0.11. Ocular Therapeutix had a negative return on equity of 56.23% and a negative net margin of 2,346.47%. Equities research analysts expect that Ocular Therapeutix will post ($1.77) earnings per share for the current fiscal year.

Institutional investors have recently added to or reduced their stakes in the company. FMR LLC increased its position in Ocular Therapeutix by 16.7% in the second quarter. FMR LLC now owns 3,711,552 shares of the biopharmaceutical company’s stock valued at $18,372,000 after buying an additional 531,995 shares during the period. Jennison Associates LLC increased its position in Ocular Therapeutix by 1.1% in the third quarter. Jennison Associates LLC now owns 3,004,521 shares of the biopharmaceutical company’s stock valued at $20,641,000 after buying an additional 31,915 shares during the period. BlackRock Fund Advisors increased its position in Ocular Therapeutix by 6.3% in the third quarter. BlackRock Fund Advisors now owns 824,426 shares of the biopharmaceutical company’s stock valued at $5,664,000 after buying an additional 48,815 shares during the period. Morgan Stanley increased its position in Ocular Therapeutix by 481.4% in the third quarter. Morgan Stanley now owns 573,309 shares of the biopharmaceutical company’s stock valued at $3,938,000 after buying an additional 474,703 shares during the period. Finally, Columbus Circle Investors increased its position in Ocular Therapeutix by 76.2% in the third quarter. Columbus Circle Investors now owns 491,204 shares of the biopharmaceutical company’s stock valued at $3,375,000 after buying an additional 212,419 shares during the period. Hedge funds and other institutional investors own 77.66% of the company’s stock.

About Ocular Therapeutix

Ocular Therapeutix, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology. The Company’s bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye.

5 Day Chart for NASDAQ:OCUL

Receive News & Stock Ratings for Ocular Therapeutix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix Inc. and related stocks with our FREE daily email newsletter.